Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. - Wikidata - awgldk - TriplyDB

Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel.

Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel.

http://www.wikidata.org/entity/Q43918762

about

Primary chemotherapy in breast cancer: The beginning of the end or the end of the beginning for the surgical oncologist?Report on the 4th European Breast Cancer Conference, Hamburg, Germany, 16-20 March 2004 Quantification of Ultrasonic Scattering Properties of In Vivo Tumor Cell Death in Mouse Models of Breast Cancer.Early prediction of therapy responses and outcomes in breast cancer patients using quantitative ultrasound spectral texture Conventional frequency ultrasonic biomarkers of cancer treatment response in vivo.Evaluation of neoadjuvant chemotherapy response in women with locally advanced breast cancer using ultrasound elastography.Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate.Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer.A Phase II trial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage II or III breast cancer: NCCTG study N0338.Diffuse optical spectroscopy measurements of healing in breast tissue after core biopsy: case study Breast cancer (non-metastatic)Prognostic imaging in neoadjuvant chemotherapy of locally-advanced breast cancer should be cost-effective Non-pegylated liposomal Doxorubicin-cyclophosphamide in sequential regimens with taxanes as neoadjuvant chemotherapy in breast cancer patients.Presentation and management of docetaxel-related adverse effects in patients with breast cancer Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer.Breast cancer local recurrence under the form of inflammatory carcinoma, treated with concurrent radiation and chemotherapy, a case report Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline.Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in wom Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy.Breast conserving surgery versus mastectomy: the influence of comorbidities on choice of surgical operation in the Department of Defense health care system NEO adjuvant chemotherapy in breast cancer: What have we learned so far?Baseline tumor oxygen saturation correlates with a pathologic complete response in breast cancer patients undergoing neoadjuvant chemotherapy.Pre-treatment differences and early response monitoring of neoadjuvant chemotherapy in breast cancer patients using magnetic resonance imaging: a systematic review.Randomized adjuvant trials in oncology: a necessity or time-consuming luxury?CD133 is a useful surrogate marker for predicting chemosensitivity to neoadjuvant chemotherapy in breast cancer.Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study Dual roles for immune metagenes in breast cancer prognosis and therapy prediction.A Phase II Trial of Neoadjuvant Chemotherapy with Genexol® (Paclitaxel) and Epirubicin for Locally Advanced Breast Cancer Association between Pathological Complete Response and Outcome Following Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients.Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival.Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy.Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial.Concurrent chemoradiotherapy for locally advanced breast cancer-time for a new paradigm?Comparison of Doxorubicin plus docetaxel neoadjuvant chemotherapy with Doxorubicin plus vinorelbine in primary breast cancer Current neoadjuvant treatment options for HER2-positive breast cancer.A Canadian national expert consensus on neoadjuvant therapy for breast cancer: linking practice to evidence and beyond

P2860

Q24795356-92A1DBFC-FE3E-4759-A7E3-4E6EB3239D07 Q24806223-0CEF94ED-3D3F-43C2-81B6-0BCA6A91E9A7 Q30392082-B30CD007-E0C7-4A99-ADA6-26A55002C06A Q30433481-6EE96CA5-90B9-4E16-9840-01E03EF447E9 Q30453647-9580C89D-C66B-4202-AE72-D241034A9FC6 Q30458231-02CBFDA8-9B93-454D-9943-522B7FEEAADA Q33348234-CCE87534-D140-4D66-A807-95C69617F21F Q33388534-A069DDE3-8743-43C0-97E0-E2B233B01071 Q33402700-6F3673CB-1738-41C1-969A-29A7958BA063 Q33414280-1E3CC5A3-1D76-4C92-B8C0-EE2173A25627 Q33446778-D01DB49B-CD1D-4DF8-AE39-EAC0F6E87CB0 Q33593185-FC0C6471-DD85-4548-8C7F-EB7B4408AEA4 Q33634964-9E88DFCB-072A-4128-BC8C-2918756B47D5 Q33698286-72000C53-3B29-43C9-ADE9-51F2F020333C Q33698446-B5A8EA83-70FD-4044-A66B-E00E3C216B5D Q33750115-EDE7D22B-956F-407C-925D-A8AC2BDA4904 Q33751728-81B7C72A-F41D-42EC-9F23-666920E362A9 Q33759404-1A43EC4D-E5FD-4B80-9ECA-6949AE012F48 Q33821528-D1E016C1-AC33-4ADF-AC35-98C429546347 Q33904763-0E178C55-E608-4DE8-A08F-088ACB4D5E00 Q34012047-F1AE7C26-1947-4608-9314-13798032E60E Q34059719-B908FAF6-BD29-4F02-88B2-ADE07B76972E Q34107526-A1999CAD-AEA0-480D-9BB7-F2DECC794A1F Q34138174-9BF583C8-4B45-403E-ACB8-917BF8A759E8 Q34331734-0A19E823-6DD0-49D8-A66A-55C34EFC3015 Q34415629-9F3B76D6-AB6B-48AE-8478-250C66894B89 Q34423520-8B559C87-3BF8-45D0-A42C-379BF761EAB0 Q34438511-98AFFE04-ABFB-4FB0-8649-E2826F222E47 Q34520174-1EE71412-1E57-4DBA-B12B-215D813A3D69 Q34558758-98374463-7552-4868-A26E-45FEB5441B29 Q34779654-A7DBA335-EFBF-435E-8460-4DE4F2D63791 Q34779690-11951C70-6A50-46B1-A5F0-B91A57EBCA75 Q34793805-56D4E025-8673-4817-BB66-C6759AB739B1 Q34816825-345D6934-B82B-4622-9830-96FC202D7B86 Q35012858-8C1E2B76-0E5A-4B91-85FF-62DAD179537D Q35060987-99B5B639-39A7-4DA0-BF41-5789DB786364 Q35072438-0CA8AB14-F4F9-4759-B17C-B65B89C1FA15 Q35142230-F00B9DB6-B27A-4010-8D2B-8C101BE2A79F Q35164938-C694618C-6105-4829-B65A-B42843FBF32C Q35239617-A5189FFF-B890-4387-B651-3FE249D134AA

P2860

Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel.

http://www.wikidata.org/entity/Q43918762

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Neoadjuvant chemotherapy in br ...... anced response with docetaxel.

@en

Neoadjuvant chemotherapy in br ...... anced response with docetaxel.

@nl

type

label

Neoadjuvant chemotherapy in br ...... anced response with docetaxel.

@en

Neoadjuvant chemotherapy in br ...... anced response with docetaxel.

@nl

prefLabel

Neoadjuvant chemotherapy in br ...... anced response with docetaxel.

@en

Neoadjuvant chemotherapy in br ...... anced response with docetaxel.

@nl

P1433

Q43918762-A1DFFD64-9886-48BA-8255-1F5473988695

P1476

Q43918762-B98E59F4-5CF7-4D03-8303-61B16BA6372E

P2093

Q43918762-2EE25746-EBB9-4443-A0DF-B8632B786CD3

Q43918762-2F5AFE46-9339-4078-9DD2-B27D1BD6668F

Q43918762-3590CDE4-B968-4EA5-8984-DC1A9D29FA44

Q43918762-3D732F55-0EB7-4251-98B3-EF84C80B4D52

Q43918762-4927D7C0-126C-4EC5-BE3E-790AEAFBEA00

Q43918762-55C48D4B-8668-481D-9313-0AA107623BFE

Q43918762-734AA81F-BD9C-4B17-8216-9CADAD9BC0D6

Q43918762-831C7083-0517-4D11-A22C-1D38714C9726

Q43918762-8D38FEC4-1D3F-4507-92F4-B6703399DACC

Q43918762-8E1F4CE3-6384-49C7-9015-6142FB5E5C1C

P304

Q43918762-3C65B4F5-1C27-4DFE-B142-8155FA767CDC

P31

Q43918762-A79D8D7E-2415-4227-A78C-135728349639

P356

Q43918762-9E9ED23C-9AAB-4D96-92A5-091A22A967E8

P407

Q43918762-66970880-1E26-4F63-AE58-FDFD9272688A

P433

Q43918762-F0E83AC6-EF6B-4E16-BF59-B61A5EA817FD

P478

Q43918762-4865A339-942A-48A5-BAD8-B2C6EE0FF348

P577

Q43918762-53B104B2-0287-45EB-8A2E-385F09D3CB30

P698

Q43918762-AF70C21A-127D-4B14-A7D8-7C1A066C61DE

P921

Q43918762-AC016F7E-C35A-4559-832E-69A7FCAB3794

P356

P1433

Journal of Clinical Oncology

P1476

Neoadjuvant chemotherapy in br ...... anced response with docetaxel.

@en

P2093

Andrew W Hutcheon

http://www.w3.org/2001/XMLSchema#string

Antoinne K Ah-See

http://www.w3.org/2001/XMLSchema#string

Fiona J Gilbert

http://www.w3.org/2001/XMLSchema#string

Iain D Miller

http://www.w3.org/2001/XMLSchema#string

Ian C Smith

http://www.w3.org/2001/XMLSchema#string

Keith N Ogston

http://www.w3.org/2001/XMLSchema#string

Leslie G Walker

http://www.w3.org/2001/XMLSchema#string

Oleg Eremin

http://www.w3.org/2001/XMLSchema#string

S Peter Eggleton

http://www.w3.org/2001/XMLSchema#string

Simon Payne

http://www.w3.org/2001/XMLSchema#string

P304

1456-1466

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.20.6.1456

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2002-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11896092

http://www.w3.org/2001/XMLSchema#string

P921